InvestorsHub Logo
Followers 11
Posts 1565
Boards Moderated 0
Alias Born 09/19/2006

Re: None

Thursday, 11/15/2018 11:21:25 AM

Thursday, November 15, 2018 11:21:25 AM

Post# of 6401
3rd Q conference call.

2.3 million in cash left. Hopefully it will last 2 quarters as the burn rate was reduced to 4.8 million through the 3rd quarter of 2018.

The Prexigebersen CML trial finally opens and is enrolling patients.

https://clinicaltrials.gov/ct2/show/NCT02923986?term=bio-path+CML&rank=1

The poster presentation looks like it will be a rehash of prior results like this conference call.

The promise of the science still exists but without the funds to continue what is the point? So much promise and so little progress.

No questions for PN. I suspect no one cares or is covering stock any longer.

https://seekingalpha.com/article/4222460-bio-path-holdings-bpth-ceo-peter-nielsen-q3-2018-results-earnings-call-transcript?page=1
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News